Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies

被引:0
作者
Jun Liu
Nian Wang
Hai-xia Dang
Bing-wei Chen
Li Zhang
Chong Zou
Cheng-liang Zhong
Ju-kai Huang
Qiong Liu
Ya-nan Yu
Meng Jiang
Wei-xiong Liang
Qi-guang Chen
Yong-yan Wang
Chun-ti Shen
Zhong Wang
机构
[1] China Academy of Chinese Medical Sciences,Institute of Basic Research in Clinical Medicine
[2] China Academy of Chinese Medical Sciences,School of Public Health
[3] Southeast University,undefined
[4] Dongfang Hospital Affiliated to Beijing University of Chinese Medicine,undefined
[5] Jiangsu Provincial Hospital of Traditional Chinese Medicine (Affiliated Hospital of Nanjing University of Traditional Chinese Medicine),undefined
[6] First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,undefined
[7] Guangdong Hospital of Traditional Chinese Medicine,undefined
[8] Changzhou Traditional Chinese Medicine Hospital,undefined
来源
Chinese Journal of Integrative Medicine | 2021年 / 27卷
关键词
data monitoring committee; Chinese Medicine Data Monitoring Committee; clinical trial; community standard; Chinese medicine;
D O I
暂无
中图分类号
学科分类号
摘要
Although there is guidance from different regulatory agencies, there are opportunities to bring greater consistency and stronger applicability to address the practical issues of establishing and operating a data monitoring committee (DMC) for clinical studies of Chinese medicine. We names it as a Chinese Medicine Data Monitoring Committee (CMDMC). A panel composed of clinical and statistical experts shared their experience and thoughts on the important aspects of CMDMCs. Subsequently, a community standard on CMDMCs (T/CACM 1323-2019) was issued by the China Association of Chinese Medicine on September 12, 2019. This paper summarizes the key content of this standard to help the sponsors of clinical studies establish and operate CMDMCs, which will further develop the scientific integrity and quality of clinical studies.
引用
收藏
页码:483 / 489
页数:6
相关论文
共 35 条
  • [1] Fleming TR(2017)Data monitoring committees: promoting best practices to address emerging challenges Clin Trials 14 115-123
  • [2] DeMets DL(2006)Committee for Medicinal Products for Human Use (CHMP) guideline on data monitoring committees Stat Med 25 1639-1645
  • [3] Roe MT(2015)Data and safety monitoring of Danhong injection in W clinical trials Journal of Chinese Pharmaceutical ences 50 375-378
  • [4] Wittes J(2016)Data monitoring committees-expect the unexpected N Engl J Med 375 1365-1371
  • [5] Calis KA(1999)ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group Stat Med 18 1905-1942
  • [6] Vora AN(2006)Operating characteristics of sample size reestimation with futility stopping based on conditional power Stat Med 25 3348-3365
  • [7] Wang L(1992)Monitoring clinical trials with a conditional probability stopping rule Stat Med 11 659-672
  • [8] Liu J(2014)Comparative effectiveness of Di’ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina Sci Rep 4 7058-undefined
  • [9] Dang HX(2015)Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial Trials 16 561-undefined
  • [10] Wang Z(2015)Danhong Injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial Trials 16 474-undefined